Phase 3 Data: “Game-changing” Oral IL-23 Blocker Shows Efficacy and Safety in PsO
Icotrokinra, a first-in-class targeted oral peptide that selectively blocks interleukin (IL)-23, demonstrated significantly higher rates of skin clearance and a favorable safety profile in adults and adolescents with moderate-to-severe plaque psoriasis, according to the first Phase 3 study, which was presented at the 2025 American Academy of Dermatology’s annual meeting in Orlando, FL. Protagonist Therapeutics […]